Cover Image
Market Research Report
Product code 
974400

Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020

Published: | GlobalData | 314 Pages | Delivery time: 1-2 business days

Price

Back to Top
Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020
Published: November 30, 2020
GlobalData
Content info: 314 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

GlobalData's Medical Devices sector report, "Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Inborn Gene or Chromosome Alterations Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Inborn Gene or Chromosome Alterations Tests are the genetic tests used to detect monogenetic disorders (like Cystic Fibrosis, Haemochromatosis, Prothrombin Mutation etc), polygenetic disorders (like Asthma , Atherosclerosis, Diabetes, Hypertension, Osteoporosis, etc), chromosomal disorders (like Down's Syndrome, Edwards Syndrome etc), polymorphisms (like HLA-Typing etc).

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inborn Gene or Chromosome Alterations Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inborn Gene or Chromosome Alterations Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Product Code: GDME1040EPD

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2.1 Inborn Gene or Chromosome Alterations Overview

3 Products under Development

  • 3.1 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • 3.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
  • 3.3 Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
  • 3.4 Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
  • 3.5 Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials

4 Inborn Gene or Chromosome Alterations - Pipeline Products under Development by Companies

  • 4.1 Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
  • 4.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development

5 Inborn Gene or Chromosome Alterations Companies and Product Overview

6 Inborn Gene or Chromosome Alterations- Recent Developments

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer

List of Tables

List of Tables

  • Table 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • Table 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
  • Table 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
  • Table 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
  • Table 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials
  • Table 6: Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
  • Table 7: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • Table 8: Aarhus University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Cystic Fibrosis Urine Test - Product Status
  • Table 10: Cystic Fibrosis Urine Test - Product Description
  • Table 11: AbaStar MDx Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: Molecular Diagnostic Test - Bipolar Disorder - Product Status
  • Table 13: Molecular Diagnostic Test - Bipolar Disorder - Product Description
  • Table 14: Molecular Diagnostic Test - Depression - Product Status
  • Table 15: Molecular Diagnostic Test - Depression - Product Description
  • Table 16: Molecular Diagnostic Test - Parkinson's Disease - Product Status
  • Table 17: Molecular Diagnostic Test - Parkinson's Disease - Product Description
  • Table 18: Molecular Diagnostic Test - Schizophrenia - Product Status
  • Table 19: Molecular Diagnostic Test - Schizophrenia - Product Description
  • Table 20: AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: Diagnostic Test - Hereditary Deafness - Product Status
  • Table 22: Diagnostic Test - Hereditary Deafness - Product Description
  • Table 23: Agena Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Sensigene Trisomy 21 Laboratory Developed Test - Product Status
  • Table 25: Sensigene Trisomy 21 Laboratory Developed Test - Product Description
  • Table 26: Alexion Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 27: SmartPanel - Product Status
  • Table 28: SmartPanel - Product Description
  • Table 29: Allele Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: RAD4CHD Test - Product Status
  • Table 31: RAD4CHD Test - Product Description
  • Table 32: Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: Diagnostic Test - IFN-Beta Resistance - Product Status
  • Table 34: Diagnostic Test - IFN-Beta Resistance - Product Description
  • Table 35: Amity University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Prenatal Screening Kit - Product Status
  • Table 37: Prenatal Screening Kit - Product Description
  • Table 38: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: PDx Pre-Symptomatic Test - Product Status
  • Table 40: PDx Pre-Symptomatic Test - Product Description
  • Table 41: Asuragen Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: Signature CF Expand - Product Status
  • Table 43: Signature CF Expand - Product Description
  • Table 44: Augusta University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 45: SUMO Gene Test - Type 1 Diabetes - Product Status
  • Table 46: SUMO Gene Test - Type 1 Diabetes - Product Description
  • Table 47: AutoGenomics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Status
  • Table 49: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Description
  • Table 50: DNA Guided Diagnostic Test - Diabetes - Product Status
  • Table 51: DNA Guided Diagnostic Test - Diabetes - Product Description
  • Table 52: DNA Guided Diagnostic Test - Obesity - Product Status
  • Table 53: DNA Guided Diagnostic Test - Obesity - Product Description
  • Table 54: INFINITI Neural Response Panel - Product Status

List of Figures

List of Figures

  • Figure 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • Figure 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
  • Figure 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
  • Figure 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
  • Figure 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials